VideoHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Other Viruses: using Wolbachia to interrupt transmission of viral infections such as Dengue, Chikungunya and Zika | Steven Kern, PhDView Video
AOAndrew OwenBSS, MSC, PhD, FSBVideoTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Long acting (LA) drug delivery in TB treatment | Andrew Owen, BSS, MSC, PhD, FSBView Video
VideoTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Lost in translation: learning from preclinical data | Gerry DaviesView Video
CPCharles PeloquinPharmDVideoTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Rifampin vs. Rifapentine: a debate over the preferred rifamycin | Charles Peloquin, PharmDView Video
VideoTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Rifampin vs. Rifapentine: a debate over the preferred rifamycin | Kelly Dooley, MD, PhDView Video
VideoTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016A new model for early clinical development of TB drugs and its application to Q203 and BTZ043 | Norbert Heinrich, MDView Video
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Pharmacokinetic Modeling and Simulation of the Interaction between Moxifloxacin and Rifapentine in Healthy Volunteers | M. ImperialView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Rifampin vs. Rifapentine: a debate over the preferred rifamycin | Kelly Dooley, MD, PhDView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Population pharmacokinetic modeling to assess the non-linear increase in exposure following increasing doses of rifampicin | R. SvenssonView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Population Pharmacokinetics of AZD5847 in Adults with Pulmonary Tuberculosis | C. PeloquinView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016A new model for early clinical development of TB drugs and its application to Q203 and BTZ043 | Norbert Heinrich, MDView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016A model-based analysis to describe bedaquiline’s exposure-response relationship and predict the impact of drug-drug interactions | E. SvenssonView Slideset
